Parkinson's - MJFF launches series of funding programmes ($ 10,000,000)

The Michael J. Fox Foundation (MJFF) has launched a new series of funding programmes: 
• Target Validation: Pre-Proposals Due: October 30, 2013;
• Therapeutic Pipeline Program: Pre-Proposals Due: October 30, 2013;
• Parkin Biology & Therapeutic Development 2013: Pre-proposals Due: June 19, 2013;
• Cognition Biomarkers RFA 2013: Pre-Proposals Due: June 19, 2013;
• LRRK2 Role in Idiopathic Parkinson’s Disease 2013: Pre-Proposals Due: June 19, 2013.

Other upcoming funding opportunities are:
• Rapid Response Innovation Awards: No deadline; Applications accepted anytime;
• Dyskinesia Challenge 2013: No deadline; applications accepted anytime up to one year in duration;
• LRRK2 Challenge 2013: No deadline; applications accepted anytime, up to one year;
• Neurotrophic Factors Challenge 2013: No deadline; applications accepted anytime, up to one year in duration.

The Michael J. Fox Foundation works tirelessly to accelerate promising research toward clinical testing and breakthroughs for Parkinson’s patients. While our strong emphasis is on funding translational and clinical research, we also support high-risk/high-reward discovery work to help keep new ideas flowing into the drug development pipeline.